Bolt Biotherapeutics Stock Current Liabilities
| BOLT Stock | USD 0.49 0.02 3.92% |
Bolt Biotherapeutics fundamentals help investors to digest information that contributes to Bolt Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Bolt Stock. The fundamental analysis module provides a way to measure Bolt Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bolt Biotherapeutics stock.
Non Current Liabilities Total is likely to gain to about 46.8 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 16.1 M in 2025. Bolt | Current Liabilities |
Bolt Biotherapeutics Company Current Liabilities Analysis
Bolt Biotherapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Bolt Biotherapeutics Current Liabilities | 9.12 M |
Most of Bolt Biotherapeutics' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bolt Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bolt Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Bolt Biotherapeutics is extremely important. It helps to project a fair market value of Bolt Stock properly, considering its historical fundamentals such as Current Liabilities. Since Bolt Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bolt Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bolt Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Bolt Current Liabilities Historical Pattern
Today, most investors in Bolt Biotherapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bolt Biotherapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bolt Biotherapeutics current liabilities as a starting point in their analysis.
Bolt Biotherapeutics Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Bolt Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Bolt Biotherapeutics has a Current Liabilities of 9.12 M. This is 99.48% lower than that of the Biotechnology sector and 98.32% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.88% higher than that of the company.
Bolt Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bolt Biotherapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bolt Biotherapeutics could also be used in its relative valuation, which is a method of valuing Bolt Biotherapeutics by comparing valuation metrics of similar companies.Bolt Biotherapeutics is currently under evaluation in current liabilities category among its peers.
Bolt Biotherapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Bolt Biotherapeutics from analyzing Bolt Biotherapeutics' financial statements. These drivers represent accounts that assess Bolt Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Bolt Biotherapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.2B | 183.3M | 48.6M | 42.3M | 48.7M | 46.3M | |
| Enterprise Value | 1.2B | 180.2M | 61.9M | 51.8M | 59.5M | 56.5M |
Bolt Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (14.41) % | ||||
| Current Valuation | (17.49 M) | ||||
| Shares Outstanding | 38.27 M | ||||
| Shares Owned By Insiders | 5.09 % | ||||
| Shares Owned By Institutions | 48.23 % | ||||
| Number Of Shares Shorted | 106.12 K | ||||
| Price To Earning | 36.55 X | ||||
| Price To Book | 0.25 X | ||||
| Price To Sales | 1.85 X | ||||
| Revenue | 7.88 M | ||||
| Gross Profit | (52.29 M) | ||||
| EBITDA | (74.34 M) | ||||
| Net Income | (69.2 M) | ||||
| Cash And Equivalents | 176.34 M | ||||
| Cash Per Share | 4.68 X | ||||
| Total Debt | 20.22 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 9.73 X | ||||
| Book Value Per Share | 1.88 X | ||||
| Cash Flow From Operations | (69.53 M) | ||||
| Short Ratio | 0.69 X | ||||
| Earnings Per Share | (1.71) X | ||||
| Target Price | 1.75 | ||||
| Number Of Employees | 100 | ||||
| Beta | 0.95 | ||||
| Market Capitalization | 18.13 M | ||||
| Total Asset | 159.78 M | ||||
| Retained Earnings | (364.29 M) | ||||
| Working Capital | 85.25 M | ||||
| Current Asset | 53.49 M | ||||
| Current Liabilities | 9.12 M | ||||
| Net Asset | 159.78 M |
About Bolt Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bolt Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bolt Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bolt Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.